Studies in Treatment Phase & Follow-up

ABCSG 22R-QoL

A survey conducted on the quality of life of breast cancer patients registered in ABCSG 22R


ABCSG 25 / PANTHER

A randomized phase III study comparing biweekly and tailored epirubicin + cyclophosphamide followed by biweekly tailored docetaxel (dtEC→dtT) (A-arm) versus three weekly epirubicin + cyclophosphamide, 5-fluorouracil followed by docetaxel (FEC→T) (B-arm) in lymph node positive or high-risk lymph node negative breast cancer patients – a continuation of the feasibility part of the SBG 2004-1 study


ABCSG 28 / Posytive

Primary Operation in SYnchronous meTastasized InVasivE breast cancer, a multicenter prospective randomized study to evaluate the use of local therapy.


ABCSG 36 / PENELOPEB / ETERNITY

Phase III trial to evaluate palbociclib (PD-0332991), a cyclin kinase 4/6 inhibitor, in patients with hormone receptor positive, HER2-negativ primary breast cancer and a high risk of relapse following neoadjuvant chemotherapy ETERNITY: Registry for long-term follow-up of safety and efficacy parameters of GBG study participants


ABCSG 39 / Aphinity

A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer.


ABCSG 41 / OlympiA

A randomised, double-blind, parallel group, placebo-controlled multi-centre phase III study to assess the efficacy and safety of olaparib vs placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2-negative breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy


ABCSG 42 / PALLAS

PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer


ABCSG 43 / INSEMA

Comparison of axillary sentinel lymph node biopsy versus no axillary surgery in patients with stage I and II invasive breast cancer and breast-conserving surgery: a randomized prospective surgical trial


ABCSG 48 / POSITIVE

A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy (POSITIVE)


ABCSG 51 / AURORA

Aiming to understand the molecular aberrations in metastatic breast cancer: The AURORA program


ABCSG 52 / ATHENE

An open-label, two-arm, randomized, single-stage phase II study of ATezolizumab in combination with dual HER2 blockade plus epirubicin as NEoadjuvant therapy for HER2-positive early breast cancer


ABCSG P02

A prospective randomized phase II trial of FOLFIRINOX alone versus FOLFIRINOX followed by radiochemotherapy in patients with locally advanced, primarily inoperable pancreatic cancer




Share on


Top